Global Natural Killer (NK) Cell Therapeutics Market Analysis and Forecast, 2019-2028 – In-depth Market Report by RationalStat | RationalStat

The report titled “NK Cell Therapeutics” assesses the global market based on application, end user, and region. A comprehensive report provides a detailed historical and future market size with trend analysis. The report underlines the market share analysis, production capacities by leading players, competition overview, strategic imperatives, annual sales figures, growth avenues, clinical trial phases, drug development analysis, production overview, and competition assessment for the target players assessed in the global NK cell therapeutics market study.

Market Overview and Dynamics: Ongoing pre-clinical and clinical development of NK cell-based therapies are propelling the market growth

The global NK cell therapeutics market is expected to grow at a robust CAGR of over 50% during the forecast period of 2022-2028. NK cells have shown promising results in various molecular and combinational therapies which have increased their adoption for treatments. Also, healthcare researchers and scientists are using NK cells as an effective tool against infectious diseases and as an anti-cancer alternative to T cells. This has pushed the clinical development of NK cell-based therapies which is acting as a pivotal growth factor for the global market.

The increasing prevalence of cancer across the globe has surged the need for the development of novel therapies for its treatment. In tumor immune surveillance, NK cells play a pivotal role which further bolsters adoption of the NK cell-based therapies globally. The growing adoption of NK cell-based therapies for the treatment of cancer and other infectious diseases is augmenting market growth. Moreover, rising awareness regarding immunotherapies among the patient population is further expected to propel market growth.

North America and Europe, collectively, are expected to generate significant revenue on the back of increased R&D efforts in the development of novel therapies for cancer treatment by the leading market players present in these regions. Players operating in the market ecosystem, are actively involved in the R&D of NK cell-based therapies for the treatment of various diseases including cancer. A large number of clinical trial applications for NK cell therapeutics have been submitted in recent times, reflecting a promising future for market growth.

Segmental Analysis

  • On the basis of application, the oncology segment is expected to hold a prominent share on account of the increasing prevalence of cancer globally and increased demand for novel therapies for cancer treatment.
  • On the basis of end users, the research center & institutes segment is set to observe the fastest growth rate on the back of increasing R&D efforts on drug and therapy development.
  • Geographically, North America is expected to dominate the global NK cell therapeutics market due to the soaring investment by leading industry players in the development of NK cell-based therapies.

Competition Analysis: Significant market consolidation is expected in the near future

The global NK cell therapeutics market is at a nascent stage and is expected to flourish in the upcoming years. Players involved in the research & development of NK cell-based therapies are heavily investing in the sector with a keen focus on oncology treatment. Product innovations, launches, partnerships, mergers & acquisitions are the identified industry trends in the global NK cell therapeutics market. For instance,

  • In August 2022, Zelluna Immunotherapy announced an investment from Takeda Ventures, Inc. (TVI), the strategic investing arm of Takeda. TVI investment joins Zelluna's latest financing round. The funds will enable the advancement of a lead TCR-NK product through manufacturing to Clinical Trial Application (CTA) / Investigational New Drug Application (IND) readiness and, continue the advancement of Zelluna's platform with additional programs reaching the preclinical stage.
  • In January 2022, Takeda announced to acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ) T Cell Engager Therapies Targeting Solid Tumors. Through the acquisition, Takeda would obtain Adaptate's antibody-based γδ T cell engager platform, including pre-clinical candidate and discovery pipeline programs. Adaptate's γδ T cell engagers are designed to specifically modulate γδ T cell-mediated immune responses at tumor sites while sparing damage to healthy cells.

Some of the leading players involved in the research & development, production, and marketing of NK cell therapeutics include Nkarta, Inc, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Affimed GmbH, Zelluna Immunotherapy, Nektar Therapeutics, XNK Therapeutics AB, ONK Therapeutics, Catarman Bio, MiNK Therapeutics, Celularity Inc., Artiva Biotherapeutics and others.

RationalStat has segmented the Global NK Cell Therapeutics Market on the basis of application, end user, and region.

  • By Application
    • Cancer
    • Gastrointestinal Diseases
    • Immunoproliferative Disorders
    • Others
  • By End User
    • Hospitals
    • Research Centers and Institutes
    • Others
  • By Region
    • North America
      • US
      • Canada
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Western Europe
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Benelux
      • Nordic
      • Rest of Western Europe
    • Eastern Europe
      • Russia
      • Poland
      • Rest of Eastern Europe
    • Asia Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • ASEAN (Indonesia, Vietnam, Malaysia, etc.)
      • Rest of Asia Pacific
    • Middle East & Africa
      • GCC
      • South Africa
      • Turkey
      • Rest of the Middle East & Africa

For more information about this report

About RationalStat LLC

RationalStat is an end-to-end US-based market intelligence and consulting company that provides comprehensive market research reports along with customized strategy and consulting studies.  The company has sales offices in India, Mexico, and the US to support global and diversified businesses. The company has over 80 consultants and industry experts, developing more than 850 market research and industry reports for its report store annually.

RationalStat has strategic partnerships with leading data analytics and consumer research companies to cater to the client’s needs. Additional services offered by the company include consumer research, country reports, risk reports, procurement intelligence, data analytics, and analytical dashboards.


Kimberly Shaw,
Content and Press Manager
RationalStat LLC
Phone: +1 302 803 5429

Leave a Reply

Your email address will not be published. Required fields are marked *